Vedolizumab superior to adalimumab in clinical remission (31 vs 22%) and mucosal healing(40 vs 28%) at week 52 when given to383 patients with moderate to severely active ulcerative colitis. Data presented at European Crohn’s and Colitis Congress. https://t.co/dXrEkzhnKh